je.st
news
Tag: pivotal
Cliffs: 2016 Is Pivotal
2015-12-30 22:58:00| Steel - Topix.net
Cliffs Natural Resources has undergone major change during the past year or so. It has exited the coal business and shed its Canadian iron ore mines, Bloom Lake, and Wabash.
Omega Protein Stock Rating Lowered by Pivotal Research
2015-10-20 18:16:33| Livestock - Topix.net
They currently have a $19.00 price objective on the stock. Pivotal Research's target price would indicate a potential downside of 0.84% from the company's current price.
Tags: research
rating
stock
protein
6 Trending Headlines: Ag producers win pivotal court decision; PLUS: Is swath grazing for you?
2015-10-05 19:14:00| Beef
What trends are important? What information do you need to know to stay informed? Check out this weeks Trending Headlines to learn more. read more
Pivotal Phase 3 Studies of Bezlotoxumab, Mercks Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
2015-09-20 18:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Plans to Submit New Drug Applications in U.S., EU and Canada in 2015 Results Presented for the First Time at ICAAC/ICC 2015 Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence, met their primary efficacy endpoint: the reduction in C. difficile recurrence through week 12 compared to placebo, when used in conjunction with standard of care antibiotics for the treatment of C. difficile. Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Ian McConnell, 973-901-5722orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
primary
studies
prevent
New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data...
2015-09-10 06:45:57| Biotech - Topix.net
Alexion Pharmaceuticals, Inc. announced today that data from the pivotal Phase 3 ARISE study evaluating the safety and efficacy of Kanumaa in children and adults with lysosomal acid lipase deficiency have been published in the September 10 issue of the New England Journal of Medicine . In the study, Kanuma met the primary endpoint of alanine aminotransferase normalization compared with placebo as well as six secondary endpoints.1 Kanuma is an innovative enzyme replacement therapy that has been approved by the European Commission for the treatment of patients of all ages with LAL-D, a genetic, chronic, and progressive ultra-rare metabolic disease in which infants, children and adults suffer multi-organ damage and premature death.
Tags: data
journal
medicine
england
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »